| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Salvatore Gentil. A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium. Expert opinion on drug safety. vol 13. issue 12. 2015-07-07. PMID:25139223. |
a safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium. |
2015-07-07 |
2023-08-13 |
Not clear |
| Andrea Fagiolini, Roberto Brugnoli, Guido Di Sciascio, Sergio De Filippis, Giuseppe Main. Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert opinion on pharmacotherapy. vol 16. issue 5. 2015-07-06. PMID:25672664. |
aripiprazole is an atypical antipsychotic with proven efficacy in schizophrenia and bipolar i disorder, with a pharmacological profile distinct from other available antipsychotics and a side-effect profile that is different from other agents in the class; these characteristics make it a possible alternative in patients requiring a change in antipsychotic treatment due to lack of efficacy or persistent side-effects. |
2015-07-06 |
2023-08-13 |
Not clear |
| Tae-Woon Kim, Hyun-Sik Kang, Joon-Ki Park, Sam-Jun Lee, Sang-Bin Baek, Chang-Ju Ki. Voluntary wheel running ameliorates symptoms of MK-801-induced schizophrenia in mice. Molecular medicine reports. vol 10. issue 6. 2015-06-19. PMID:25323073. |
abilify (aripiprazole), a drug used to treat human schizophrenia patients, was used as the positive control. |
2015-06-19 |
2023-08-13 |
mouse |
| Marc De Hert, Anna Eramo, Wally Landsberg, Dusan Kostic, Lan-Feng Tsai, Ross A Bake. Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis. Neuropsychiatric disease and treatment. vol 11. 2015-06-11. PMID:26064048. |
efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis. |
2015-06-11 |
2023-08-13 |
Not clear |
| Takeshi Suzuki, Kazuo Mihara, Akifumi Nakamura, Shoko Kagawa, Goyo Nagai, Kenji Nemoto, Tsuyoshi Kond. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Therapeutic drug monitoring. vol 36. issue 5. 2015-06-01. PMID:24682161. |
effects of genetic polymorphisms of cyp2d6, cyp3a5, and abcb1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in japanese patients with schizophrenia. |
2015-06-01 |
2023-08-12 |
Not clear |
| Takeshi Suzuki, Kazuo Mihara, Akifumi Nakamura, Shoko Kagawa, Goyo Nagai, Kenji Nemoto, Tsuyoshi Kond. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Therapeutic drug monitoring. vol 36. issue 5. 2015-06-01. PMID:24682161. |
we studied the effects of various factors, including genetic polymorphisms of the cytochrome p450 (cyp) 2d6, cyp3a5, and abcb1, age, gender, and smoking habit on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in 89 patients with schizophrenia (46 males, 43 females). |
2015-06-01 |
2023-08-12 |
Not clear |
| Matt Shirley, Caroline M Perr. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. vol 74. issue 10. 2015-05-25. PMID:24969315. |
aripiprazole (abilify maintena®): a review of its use as maintenance treatment for adult patients with schizophrenia. |
2015-05-25 |
2023-08-13 |
Not clear |
| Matt Shirley, Caroline M Perr. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. vol 74. issue 10. 2015-05-25. PMID:24969315. |
recently, an intramuscular long-acting injectable (lai) depot formulation of aripiprazole (abilify maintena(®)) (aripiprazole lai) has been approved for use as a treatment for schizophrenia in adults. |
2015-05-25 |
2023-08-13 |
Not clear |
| Matt Shirley, Caroline M Perr. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. vol 74. issue 10. 2015-05-25. PMID:24969315. |
the efficacy of aripiprazole lai as a maintenance treatment for schizophrenia has been demonstrated in randomized clinical trials. |
2015-05-25 |
2023-08-13 |
Not clear |
| Matt Shirley, Caroline M Perr. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. vol 74. issue 10. 2015-05-25. PMID:24969315. |
in the trials, aripiprazole lai was more effective than placebo, and noninferior to oral aripiprazole, in delaying relapse and in reducing relapse rates in schizophrenia. |
2015-05-25 |
2023-08-13 |
Not clear |
| Matt Shirley, Caroline M Perr. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. vol 74. issue 10. 2015-05-25. PMID:24969315. |
thus, aripiprazole lai is a valuable new treatment option for adult patients with schizophrenia. |
2015-05-25 |
2023-08-13 |
Not clear |
| Peter J Weiden, Leslie Citrome, Gus Alva, Matthew Brams, Ira D Glick, Richard Jackson, Greg Mattingly, Farid Kianifard, Xiangyi Meng, Linda Pestreich, Marla Hochfeld, Adam Winsec. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophrenia research. vol 153. issue 1-3. 2015-04-22. PMID:24529610. |
a trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. |
2015-04-22 |
2023-08-12 |
Not clear |
| Peter J Weiden, Leslie Citrome, Gus Alva, Matthew Brams, Ira D Glick, Richard Jackson, Greg Mattingly, Farid Kianifard, Xiangyi Meng, Linda Pestreich, Marla Hochfeld, Adam Winsec. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophrenia research. vol 153. issue 1-3. 2015-04-22. PMID:24529610. |
in a 12-week randomized open-label trial, adults diagnosed with schizophrenia experiencing inadequate efficacy and/or poor tolerability on risperidone, olanzapine, or aripiprazole were randomized to switch to iloperidone either gradually (ie, down-titration of current therapy over the first 2weeks [to 50% on day 1, 25% by week 1, 0% by week 2]) or immediately. |
2015-04-22 |
2023-08-12 |
Not clear |
| R Madelaine Paredes, Marlon Quinones, Ketan Marballi, Xiaoli Gao, Celina Valdez, Seema S Ahuja, Dawn Velligan, Consuelo Walss-Bas. Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome. The international journal of neuropsychopharmacology. vol 17. issue 8. 2015-04-14. PMID:24565079. |
we performed a comprehensive metabolomic profiling of 60 schizophrenia patients undergoing treatment with sgas that puts them at high (clozapine, olanzapine), medium (quetiapine, risperidone), or low (ziprasidone, aripiprazole) risk for developing mets, compared to a cohort of 20 healthy controls. |
2015-04-14 |
2023-08-12 |
Not clear |
| Erratum: Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]. Neuropsychiatric disease and treatment. vol 11. 2015-04-08. PMID:25848284. |
erratum: effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [corrigendum]. |
2015-04-08 |
2023-08-13 |
Not clear |
| Xieli Guo, Dali Lu, Yugang Jian. Aripiprazole-associated tic in a schizophrenia patient. Neuropsychiatric disease and treatment. vol 11. 2015-04-07. PMID:25848286. |
we present the first case, to our knowledge, of an adult schizophrenia patient who developed tics during treatment with aripiprazole. |
2015-04-07 |
2023-08-13 |
Not clear |
| Leslie Citrome, Siddhesh A Kamat, Christophe Sapin, Ross A Baker, Anna Eramo, Jesse Ortendahl, Benjamin Gutierrez, Karina Hansen, Tanya G K Bentle. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of medical economics. vol 17. issue 8. 2015-03-31. PMID:24758296. |
cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the united states. |
2015-03-31 |
2023-08-13 |
Not clear |
| Leslie Citrome, Siddhesh A Kamat, Christophe Sapin, Ross A Baker, Anna Eramo, Jesse Ortendahl, Benjamin Gutierrez, Karina Hansen, Tanya G K Bentle. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of medical economics. vol 17. issue 8. 2015-03-31. PMID:24758296. |
to develop a decision-analytic model to estimate the cost-effectiveness of initiating maintenance treatment with aripiprazole once-monthly (aom) vs paliperidone long-acting injectable (plai) once-monthly among patients with schizophrenia in the us. |
2015-03-31 |
2023-08-13 |
Not clear |
| Rayees Ahmad Wani, Mansoor Ahmad Dar, Rajesh Kumar Chandel, Yasir Hassan Rather, Inaamul Haq, Arshad Hussain, Altaf Ahmad Mall. Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatric disease and treatment. vol 11. 2015-03-20. PMID:25792838. |
effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. |
2015-03-20 |
2023-08-13 |
human |
| Rayees Ahmad Wani, Mansoor Ahmad Dar, Rajesh Kumar Chandel, Yasir Hassan Rather, Inaamul Haq, Arshad Hussain, Altaf Ahmad Mall. Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatric disease and treatment. vol 11. 2015-03-20. PMID:25792838. |
keeping this fact in mind, we planned this open-label study to see the effect on various metabolic parameters after switching stable schizophrenia subjects, who had developed metabolic syndrome on olanzapine, to aripiprazole. |
2015-03-20 |
2023-08-13 |
human |